A leading cannabinoid researcher has urged the industry to dig deeper into the therapeutic possibilities of the cannabis plant and to adopt a more scientific mindset in its continuing efforts to develop medicines.

Hunter Land, vice president of research and development at US-based Biopharmaceutical Research Company, said too many people are “stuck in the past” and wrongly categorise cannabis and its therapeutic value based on the appearance of the plant.

Hunter Land: “Does anyone have a favourite strain of apple or tomato? I don’t.” (Photo: Medicinal Cannabis Industry Australia)

He also rejected the word “strain” in the context of cannabis – suggesting it is not scientifically recognised language in botanic circles – and described full spectrum and broad spectrum as “ambiguous” phrases that create an impression of administering “mystery soup” to patients.

“Does anyone have a favourite strain of apple or tomato? I don’t. I think it strange,” he said.

Land, who became GW Pharma’s first full-time R&D staffer and played a key role in the development of Epidyolex and Sativex, told delegates at the ACannabis conference in Melbourne that it was time to move beyond the focus on THC and CBD.

“We need to look into these other cannabinoids,” he said. “We’ve been beating this course of THC and CBD forever and the countless different ratios. There are 148 other cannabinoids. Who is going to be the first to look into these and get some human data?”

He said there was an “opportunity” to be the first to do so, reminding the audience that GW Pharma was the first to push Epidyolex and ultimately sold for US$7.2 billion.

“There is a rewarding avenue for patients and for companies to study this appropriately and to look into some of these other cannabinoids,” he said.

“I don’t see a future where healthcare providers are going to say ‘oh yes, this patient needs four grams of bubba kush’.”

hunter land, vice president, biopharmaceutical research company

There is also a growing need to be more specific in terms of the ingredients in cannabis medication and the indications it is targeting, he said.

While acknowledging isolate as acceptable terminology, broad spectrum and full spectrum are unhelpful and vague, Hunter said, even though they are used by the Therapeutic Goods Administration (TGA).

“Isolate makes sense, but full spectrum and broad spectrum are ambiguous terms. One contains THC and this ‘other stuff’, so it’s a mystery soup. The other has no THC, but it’s still a mystery soup.

“Think about how many compounds we’ve got. We’ve got about 150 different cannabinoids. And the only distinction we’re drawing is THC or no THC, and the varying ratios of all these other components.

“I would encourage people to be very specific about what’s in your particular medicine… or what you’re researching, and understand how those constituents can play an important role in treating patients.”

In addition, the industry should be looking to target more specific indications rather than categorising conditions in broad terms.

To say cannabis treats pain is too ill-defined, Land said.

“Is it osteoporosis of the knee, is it fibromyalgia? If we can look more closely into the specifics then we’ll be able to better treat patients, and that’s what we all want, right?

“We don’t want patients to fail treatment because we’re not dosing them correctly.”

Turning his attention to “strains”, Land said he associates the term with “Covid-19 and E.coli” rather than cannabis.

“Cannabis has had a tough time and I don’t think associating it with terms that are not linked to accepted botany is helpful,” the former Canopy Growth scientific director said in his presentation, adding that strains are simply “branding”.

Photo: Medicinal Cannabis Industry Australia

“I don’t see a future where healthcare providers are going to say, ‘oh yes, this patient needs four grams of  bubba kush’. That’s not what healthcare practitioners are used to. It’s certainly not what my grandma is used to. She is used to being told ‘this is your dose, this is your medicine, this is what you should take and how you should take it’,”

“Broadly, that is not where the industry currently is. I would like to see it move that way if we really want to help patients with unmet medical needs and deliver it in a safe manner.”

Even the attitude towards the plant itself needs to change if the industry is to progress, he added.

With so much “inner breeding” of cannabis, determining the therapeutic value of plants based on their appearance is no longer accurate.

“Looking at a plant and determining this short, fat plant is good for sleep and this tall skinny one is good for pain… we can’t judge a plant by how it looks,” he said.

“We’ve got technology now where we can look at the chemical constituents and get some idea of how these plants should be used and what is meaningful in their content.”

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment